MIT Koch Institute
November 13, 2020
Foundation Medicine, co-founded by KI member Eric Lander, has announced two FDA approvals for two of its diagnostic tools—a blood-based biopsy to identify patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer, and a genomic test to seek out patients who express the NTRK1/2/3 gene fusions in a range of solid tumors.